Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, and more from our membership. We all appreciate your interest in our practice, and learning more about liver disease, new treatments that are available, health and wellness, and the prevention of disease. Here is the latest from Liver Specialists of Texas. Colon Cancer Video: Colon cancer is the number three cancer that adults are at risk for. We recently posted a video that is a perfect example of a patient who neglected rectal bleeding, only to find out there was a large polyp looming in his colon. To view the video, click here. New Hepatitis C Research Opportunities: We continue to participate in clinical research studies for hepatitis C that are available for those either naive to HCV therapy (never treated) or those that have …
Dr. Khaderi discussed liver disease.
Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, jobs and more from our membership. Yesterday, the FDA give approval to Boceprevir, the first in-class direct acting agent against hepatitis C. This is a long awaited announcement, and great news for patients and providers caring for hepatitis C. A You Tube video is available for review, with Dr. Galati's discussion of how patients will be evaluated and considered for treatment with Boceprevir. Boceprevir Receives FDA Approval: A You Tube Video A You Tube video of the announcement by Dr. Joe Galati is posted, discussing how Liver Specialists of Texas will evaluate and treat both new and old patients with Boceprevir. After years of research, and great anticipation by patients and physicians involved in the care of patients with hepatitis C, Boceprevier was finially approved yesterday. Yesterday …
A You Tube video of the announcement by Dr. Joe Galati is posted, discussing how Liver Specialists of Texas will evaluate and treat both new and old patients with Boceprevir. After years of research, and great anticipation by patients and physicians involved in the care of patients with hepatitis C, Boceprevier was finially approved yesterday. Yesterday was a very important day for those of us involved in the care of patients with hepatitis C, as well as the millions of individuals affected by it. I received word yesterday afternoon that the FDA has approved boceprevir for the treatment of G1 CHC in previously untreated patients and patients who have failed previous interferon and ribavirin therapy. Boceprevir is the first in class direct acting antiviral to be FDA approved for CHC. Manufactured by Merck pharmaceutical company, the …
A new financial report by Conatus, a company who is involved with HCV drug development, reports continued investment in their new HCV drugs. We are fortunate that we are conducting studies with their new agents, with good results. For more information, read the blog entry here.
Dr. Galati posted a blog entry from Berlin where he is attending the European Association for the Study of Liver Disease. Read the entire blog here.
Dr. Galati and Liver Specialists of Texas are 2011 supporters of the First Colony Dream League. First Colony Dream League is a Little League program in Sugar Land, Texas. The Dream League is a division of First Colony Little League (FCLL) and was established in Spring 2007. The Dream League roster is approximately 60 physically- and/or mentally- challenged players. In addition, the league has an "Angels in the Outfield" program, where approximately 150 teenage boys and girls from Ft. Bend area schools volunteer to assist Dream League players during the game, becoming a loyal buddy in the process. View the opening day video here.
OraSure Technologies Rapid Hepatitis C Test has been submitted to the FDA for a CLIA waiver, which would allow greater availability to this screening hepatitis C test for those at risk for hepatitis C. Read Dr. Galati's blog entry for more details.
Dr. Galati recently narrated this You Tube video on The Five Most Common Questions Liver Transplant Patients Ask. If you have additional questions, contact us.
There is great excitement regarding the soon to be FDA approval of both Telaprevir and Boceprevir, in the treatment of chronic heaptitis C. Read here for more information on Dr. Galati's opinion on what will be coming later this summer.